MXPA03009277A - Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata. - Google Patents

Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata.

Info

Publication number
MXPA03009277A
MXPA03009277A MXPA03009277A MXPA03009277A MXPA03009277A MX PA03009277 A MXPA03009277 A MX PA03009277A MX PA03009277 A MXPA03009277 A MX PA03009277A MX PA03009277 A MXPA03009277 A MX PA03009277A MX PA03009277 A MXPA03009277 A MX PA03009277A
Authority
MX
Mexico
Prior art keywords
health
related quality
life
prostate cancer
adjusted time
Prior art date
Application number
MXPA03009277A
Other languages
English (en)
Spanish (es)
Inventor
Amitabh Singh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA03009277A publication Critical patent/MXPA03009277A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03009277A 2001-04-11 2002-04-11 Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata. MXPA03009277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08
PCT/US2002/011397 WO2002085351A1 (en) 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Publications (1)

Publication Number Publication Date
MXPA03009277A true MXPA03009277A (es) 2004-03-10

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009277A MXPA03009277A (es) 2001-04-11 2002-04-11 Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata.

Country Status (10)

Country Link
EP (1) EP1379238A1 (enExample)
JP (1) JP2005503339A (enExample)
CN (1) CN1514727A (enExample)
AR (1) AR033465A1 (enExample)
BR (1) BR0205970A (enExample)
CA (1) CA2442591A1 (enExample)
IL (1) IL158071A0 (enExample)
MX (1) MXPA03009277A (enExample)
PE (1) PE20021032A1 (enExample)
WO (1) WO2002085351A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US20080085313A1 (en) * 2006-05-15 2008-04-10 Given Bruce D Methods and compositions for treatment of sleep apnea
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101234T2 (tr) * 1997-08-04 2002-06-21 Abbott Laboratories Endotelin antagonistleri.

Also Published As

Publication number Publication date
AR033465A1 (es) 2003-12-17
CA2442591A1 (en) 2002-10-31
EP1379238A1 (en) 2004-01-14
JP2005503339A (ja) 2005-02-03
BR0205970A (pt) 2003-09-30
WO2002085351A1 (en) 2002-10-31
IL158071A0 (en) 2004-03-28
PE20021032A1 (es) 2002-11-12
CN1514727A (zh) 2004-07-21

Similar Documents

Publication Publication Date Title
WO2004052238A3 (en) Phototherapy bandage
ZA200203431B (en) Therapeutic use.
Millet et al. Incorporation of microchips to facilitate denture identification by radio frequency tagging
PL361909A1 (en) A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
AU6232099A (en) Method and apparatus for determining autofluorescence of skin tissue
CA2502394A1 (en) Surgical articles
IL161978A0 (en) Method for treating cervical cancer
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
GB0001309D0 (en) Valve arrangement
AU2002243495A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
AU2002343047A1 (en) Quinazoline derivatives for the treatment of t cell mediated diseases
DK1992695T3 (da) Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf
MXPA03009277A (es) Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata.
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
IL151932A0 (en) Use of fulvestrant in the treatment of resistant breast cancer
AU2002257139A1 (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
HK1061650A (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
UY27257A1 (es) Composición farmacéutica para su uso en la modulación favorable de la calidad de vida relacionada con la salud y progresión temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cáncer de próstata
AU2002329000A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
AU2003229876A1 (en) Tumour associated antigens
AU3872800A (en) Face or nose mask for non-invasive ventilation of patients in general
HK1068060A (en) Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
Board Ewing sarcoma and undifferentiated small round cell sarcomas of bone and soft tissue treatment (PDQ®): health professional version